This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.View NKTR key stats
Nektar Therapeutics Inc - NKTR - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Nektar Therapeutics Inc as a
Sell with a ratings score of D.
Report Snippet: We rate Nektar Therapeutics Inc (NKTR) a Sell.
This is based on the convergence of positive investment measures, which should help this stock outperform the majority
of stocks that we rate. The company's strengths can be seen in multiple areas, such as its solid stock price performance,
growth in earnings per share, revenue growth, notable return on equity and expanding profit margins. Although the company
may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.